Researcher, Director of Molecular Diagnostics Laboratory, Medical Laboratory, Bachelor of Science, Shanghai Medical University, Postdoctoral Fellow, The University of Oklahoma Health Medicine Center.

He graduated from Tongji Medical University in 1989 with a master's degree in pediatric hematology. From 1994 to 1999, he was a postdoctoral researcher at the University of Oklahoma Health Medicine Center. His research interests include early detection and screening of tumors.

From 1999 to 2003, he was a research assistant in the Department of Biochemistry and Molecular Biology of the University of Oklahoma Health Medical Center. He is mainly engaged in the molecular cloning of glycosyl transferase after protein translation, glycosylation and its gene regulation. From 2003 to 2004, he was a senior researcher at the American Cancer Institute (NCI) Cancer Early Detection Biomarker Reference Laboratory, Department of Clinical Pathology and Laboratory Medicine, University of California, Los Angeles, and participated in NCI's prostate cancer, lung cancer, rectal cancer, and Biomarker detection and quality control for early screening programs for ovarian cancer. In 2005, he was a senior researcher at the Oklahoma Medical Research Foundation in the United States, where he was involved in the monitoring and control and treatment of biological bacterial infections.

In August 2006, he joined Nordic Biotechnology (Beijing) Co., Ltd. (Danish-owned) as the chief operating officer, responsible for the establishment of the company, the laboratory setup and the company's comprehensive R&D and operation management. He established the company's biomarker and drug screening research and development technology platform and in vitro diagnostic reagent production platform, and hosted more than 20 projects including R&D and drug screening for biomarker detection of chronic degenerative diseases, including 3 The biomarker detection method and one drug treatment method are internationally patented.

Since 2012, he has also served as the head of the Nordic International Biochemical Pathology Research Center (Beijing) Co., Ltd. (Danish-owned), responsible for the management and operation of the company's CAP-certified medical laboratory. In 2014, he was employed by Shanghai Huayi Epp Medical Laboratory, where he was the chief operating officer. The company was established by the University of California, Los Angeles and Shenzhen Huaxue Testing. Under his leadership, China Testing Epp established and set up molecular pathology, blood, biochemistry, immunity according to the requirements of ISO15189 and the College of American Pathologists (CAP) and other international quality standards management systems. Complete laboratory of testing medicine for microbiology, cell and molecular genetics.

More than 30 years of experience in biomedical laboratories in China and the United States, specializing in the development of biomarker detection methods, and the application of biomarkers to disease risk assessment, early diagnosis, prognosis and drug screening and drug efficacy monitoring, with rich quality control and quality assurance experience. He is familiar with the requirements and technical guidelines of CAP, CLIA and GCP/GLP, and has published more than 50 research papers in medical journals at home and abroad. He was a member of the American Society for Cancer Research.